X

1. McInnes IB, Liew FY. Nat Clin Pract Rheumatol. 2005;1(1):31-39.

2. Firestein GS. Nature. 2003;423(6937):356-361.

3. Malemud CJ. Integr J Mol Med. 2017;18(3). Pii:E484.

4.Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. Drugs. 2017;77(5):521-546.

5. Emery P, McInnes IB, van Vollenhoven R, Kraan MC. Rheumatology (Oxford). 2008;47(4):392-398.

6. Kirwan JR. J Rheumatol. 1999;26(3):720-725

7. Hodge JA, Kawabata TT, Krishnaswami S, et al. Clin Exp Rheumatol. 2016;34(2):318-328.

The pathway to inflammation

The JAK-STAT pathway plays a central role in chronic inflammatory diseases, such as rheumatoid arthritis (RA).3,4

In RA, inflammation is the major contributor to disability in early disease; radiographic progression dominates disability later in the disease process.5

Disease progression in RA6

Reproduced with permission from The Journal of Rheumatology and author Professor John R. Kirwan. All rights reserved.

Dysregulation of immune response ignites the uncontrolled inflammation of RA, which is fuelled by excessive signalling via the JAK-STAT pathway.3,7
Excessive signalling via the JAK-STAT pathway fuels inflammation.1
The pathogenesis of inflammatory diseases
For news on the partnership’s continuing innovation in RA, subscribe here.
References: 1. McInnes IB, et al. Nat Clin Pract Rheumatol. 2005;1:31-39. 2. Firestein GS. Nature. 2003;423:356-361. 3. Malemud CJ. Int J Mol Sci. 2017;18(3). Pii:E484. 4. Banerjee S, et al. Drugs. 2017;77(5):521-546. 5. Emery P, et al. Rheumatology (Oxford). 2008;47(4):392-398. 6. Kirwan JR. J Rheumatol. 1999;26:720-725. 7. Hodge JA, et al. Clin Exp Rheumatol. 2016;34(2):318-328.